• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Serina Therapeutics Inc.

    8/23/24 5:21:42 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on August 23, 2024

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    SERINA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-1436829

    (State of incorporation)

     

    (I.R.S. Employer Identification No.)

     

    601 Genome Way,    
    Suite 2001    
    Huntsville, Alabama   35806
    (Address of Principal Executive Offices)   (Zip Code)

     

    Serina Therapeutics, Inc. 2024 Inducement Equity Plan

    (Full title of the plan)

     

    Steven Ledger

    Interim Chief Executive Officer

    Serina Therapeutics, Inc.

    601 Genome Way, Suite 2001

    Huntsville, Alabama 35806

    (Name and address of agent for service)

     

    (256) 327-9630

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Scott Ludwig

    Stephen Hinton

    Bradley Arant Boult Cummings LLP

    200 Clinton Avenue Huntsville Alabama 35801

    (256) 517-5100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information

     

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants in the Serina Therapeutics, Inc. 2024 Inducement Equity Plan as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Securities and Exchange Commission (the “Commission”) but constitute, along with the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Form S-8, a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    Serina Therapeutics, Inc. (the “Company”) will furnish without charge to each person to whom the prospectus is delivered, upon the written or oral request of such person, a copy of any and all of the documents incorporated by reference in Item 3 of Part II of this Registration Statement, other than exhibits to such documents (unless such exhibits are specifically incorporated by reference to the information that is incorporated) and any other documents required to be delivered pursuant to Rule 428(b) under the Securities Act. Those documents are incorporated by reference in the Section 10(a) prospectus. Requests should be directed to the Secretary of the Company at the address and telephone number on the cover of this Registration Statement.

     

    I-1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    We incorporate by reference in this Registration Statement the documents listed below, excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):

     

    ●our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 22, 2024 (“Annual Report”);

     

    ●our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and June 30, 2024 filed with the SEC on May 14, 2024 and August 9, 2024, respectively;

     

    ●all other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2023; and

     

    ●the disclosures set forth under the caption “Description of Capital Stock” in the Company’s Registration Statement on Form S-1 (File No. 333-279121), filed with the SEC on May 3, 2024, and any other amendment or report filed for the purpose of updating such description.

     

    In addition, any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with SEC rules shall not be deemed incorporated by reference into this Registration Statement.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in or deemed to be part of this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes that statement. Any statement contained in a document that is deemed to be incorporated by reference or deemed to be part of this Registration Statement after the most recent effective date may modify or replace existing statements contained in this Registration Statement. Any such statement so modified or replaced shall not be deemed, except as so modified or replaced, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities

     

    Not Applicable.

     

    Item 5. Interests of Named Experts and Counsel

     

    Not Applicable.

     

    Item 6. Indemnification of Directors and Officers

     

    Section 145 of the Delaware General Corporation Law (the “DGCL”) permits a corporation, under specified circumstances, to indemnify its directors, officers, employees and agents against expenses (including attorneys’ fees) and other liabilities actually and reasonably incurred by them as a result of any suit (other than a suit brought by or in the right of the corporation) brought against them in their capacity as such, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to believe their conduct was unlawful. Section 145 of the DGCL also provides that directors, officers, employees and agents may also be indemnified against expenses (including attorneys’ fees) incurred by them in connection with a suit brought by or in the right of the corporation if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification may be made, unless otherwise determined by the court, if such person was adjudged liable to the corporation.

     

    The DGCL also provides that the indemnification described above will not be deemed exclusive of other indemnification that may be granted by a corporation pursuant to its by-laws, disinterested directors’ vote, stockholders’ vote, agreement or otherwise.

     

    II-2

     

     

    The DGCL also provides corporations with the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation in a similar capacity for another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against him or her in any such capacity, or arising out of his or her status, whether or not the corporation would have the power to indemnify him or her against such liability as described above.

     

    The Company’s Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) provides that no director of the Company, and no officer of the Company serving in such capacity, shall be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer to the fullest extent permissible under the DGCL or other Delaware law.

     

    The Company’s Amended and Restated Bylaws (“Bylaws”) provide that, to the fullest extent not prohibited by the DGCL or any other applicable law, the Company shall indemnify its directors and executive officers; provided, however, that the Company may modify the extent of such indemnification by individual contracts with its directors and executive officers.

     

    The above discussion of the DGCL and the Certificate of Incorporation and Bylaws is not intended to be exhaustive and is qualified in its entirety by such statutes, the Certificate of Incorporation and the Bylaws.

     

    The Company has entered into indemnification agreements with each of the Company’s directors and officers. These agreements provide that the Company will indemnify each of their directors officers to the fullest extent permitted by law and the Certificate of Incorporation and Bylaws.

     

    The Company maintains liability insurance for the benefit of its directors and officers.

     

    Item 7. Exemption from Registration Claimed

     

    Not Applicable.

     

    II-3

     

     

    Item 8. Exhibits

     

    Exhibit No.   Description of Exhibit
         
    5.1 *   Opinion of Bradley Arant Boult Cummings LLP as to the validity of the securities being registered.
    10.1*   Serina Therapeutics Inc. 2024 Inducement Equity Plan.
    23.1 *   Consent of WithumSmith+Brown, PC
    23.2 *   Consent of Frazier & Deeter, LLC
    23.3   Consent of Counsel (included in Exhibit 5.1).
    24.1   Power of Attorney (contained on the signature page hereto).
    107*   Filing Fee Table

     

    * Filed herewith

     

    II-4

     

     

    Item 9. Undertakings

     

    (a) The Company hereby undertakes:

     

    (1)To file during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement;

     

    (ii)to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that, paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered hereby which remain unsold at the termination of the offering.

     

    (b)The Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Huntsville, State of Alabama, on August 23, 2024.

     

      SERINA THERAPEUTICS, INC.
       
      By: /s/ Steven Ledger
        Steven Ledger
        Interim Chief Executive Officer

     

    II-6

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven Ledger and Balkrishan (Simba) Gill, and each of them, his or her true and lawful attorneys-in-fact and agents with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8 with any completions, additions, deletions or other changes that Mr. Ledger or Mr. Curhan shall deem necessary, appropriate or advisable, to sign any or all amendments to this Registration Statement on Form S-8, including post-effective amendments, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents, or any of them, or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Balkrishan (Simba) Gill   Executive Chairman of the Board of Directors   August 23, 2024
    Balkrishan (Simba) Gill        
             
    /s/ Steven Ledger   Interim Chief Executive Officer and Director   August 23, 2024
    Steven Ledger   (Principal Executive Officer)    
             
    /s/ Gregory S. Curhan   Chief Financial Officer   August 23, 2024
    Gregory S. Curhan   (Principal Financial and Accounting Officer)    
             
    /s/ Gregory Bailey   Director   August 23, 2024
    Gregory Bailey        
             
    /s/ Remy Gross   Director   August 23, 2024
    Remy Gross        
             
    /s/ J. Milton Harris   Director   August 23, 2024
    J. Milton Harris        
             
    /s/ Richard Marshall   Director   August 23, 2024
    Richard Marshall        
             
    /s/ Steven Mintz   Director   August 23, 2024
    Steven Mintz        

     

    II-7

     

    Get the next $SER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    7/14/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $SER
    SEC Filings

    View All

    SEC Form S-3 filed by Serina Therapeutics Inc.

    S-3 - Serina Therapeutics, Inc. (0001708599) (Filer)

    1/30/26 5:19:04 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    1/28/26 4:03:10 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Serina Therapeutics Inc.

    144 - Serina Therapeutics, Inc. (0001708599) (Subject)

    1/20/26 4:20:22 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Serina Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $15.00

    7/14/25 8:54:25 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

    "Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"  Featuring Serina Therapeutics' CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sectorMeet with Serina's CEO Steven LedgerRegister at New-FDA-Era.TribePublic.com HUNTSVILLE, AL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Serina's CEO, Steven Ledger will present at Tribe Public's Webinar Presentation a

    2/3/26 6:00:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

    - Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson's disease. The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a plan

    1/28/26 4:12:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

    HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, received a notice from the New York Stock Exchange ("NYSE") that it is below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE's listing standards set forth in Part 10 of the NYSE American Company Guide ("Company Guide"), because the Company reported stockholders' equity of $1.6 million as of September 30, 2025, and has had losses in three

    1/15/26 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/19/24 4:05:12 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/24/24 4:30:06 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/20/24 6:59:29 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Moreadith Randall exercised 6,500 shares at a strike of $0.06 and sold $19,680 worth of shares (6,500 units at $3.03) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    2/3/26 12:35:37 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 6,500 shares at a strike of $0.06 and sold $23,186 worth of shares (6,500 units at $3.57) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    1/29/26 12:54:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 2,500 shares at a strike of $0.06 and sold $7,375 worth of shares (2,500 units at $2.95) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    1/23/26 12:35:09 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    View All

    Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

    HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development. Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics,

    12/11/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

    - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

    5/22/25 4:50:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

    HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

    2/12/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    12/9/24 4:45:59 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

    SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    11/14/24 5:09:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    7/5/24 4:01:13 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Financials

    Live finance-specific insights

    View All

    Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2025, along with key recent updates. Steve Ledger, Chief Executive Officer of Serina, stated, "The FDA's alignment with our plan to advance SER-252 under a 505(b)(2) NDA pathway, and its recognition of the Phase 1b trial as registrational, represents a key milestone for Serina. This outco

    11/13/25 6:10:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. "We're proud of the momentum we've built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurologic

    8/11/25 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

    HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the "Annual Meeting"). The time and location of the Annual Meeting will be set forth in the Serina's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina's 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pur

    7/1/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care